Skip to main content
Past Event

Promoting continuous manufacturing in the pharmaceutical sector

Over the past decade, drug shortages and product recalls in the U.S. have occurred at unprecedented rates, limiting patient access to critical medicines and undermining health care. A majority of these shortages and recalls have been due to manufacturing quality issues. In response to these problems, and as part of its ongoing efforts to ensure a continuous supply of high-quality pharmaceuticals in the U.S., the U.S. Food and Drug Administration (FDA) is pursuing a range of strategies designed to improve the flexibility, reliability, and quality of pharmaceutical manufacturing. Among these strategies is the promotion of new manufacturing technologies, including continuous manufacturing. Continuous manufacturing offers several important advantages over current approaches to manufacturing and has the potential to significantly mitigate the risks of quality failures. At present, however, these technologies and processes are not widely used by the pharmaceutical industry, and there remain a number of barriers to their broader adoption. In collaboration with a range of stakeholders, FDA is currently exploring ways in which it can help to address these barriers and facilitate the uptake of new manufacturing technologies.

Under a cooperative agreement with FDA, the Center for Health Policy at Brookings held a workshop on October 19 entitled “Promoting Continuous Manufacturing in the Pharmaceutical Sector.” This workshop provided an opportunity for industry, academia, and government partners to identify the major barriers to the adoption of continuous manufacturing, discuss regulatory policies and strategies that could help to address those barriers, and explore approaches to improving public and private sector alignment and collaboration to promote the adoption of continuous manufacturing.

Agenda

Welcome, overview, and meeting objectives

Promoting the adoption of continuous manufacturing in the pharmaceutical industry: The FDA perspective

J

Janet Woodcock

Director, Center for Drug Evaluation and Research - US Food and Drug Administration

Session I: Assessing the current landscape and future direction for continuous manufacturing

A

Alastair Florence

Professor of Pharmaceutical Science & Director, EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation - University of Strathclyde

M

Markus Krumme

Head of the Continuous Manufacturing Unit - Novartis Pharmaceuticals

F

Fernando Muzzio

Director, Center for Structured Organic Particulate Systems, & Distinguished Professor, Chemical and Biochemical Engineering - Rutgers University

L

Lawrence Yu

Deputy Director, Office of Pharmaceutical Quality - U.S. Food and Drug Administration

Session II: Improving scientific and technical knowledge to support continuous manufacturing

R

Richard Braatz

Edwin R. Gilliland Professor of Chemical Engineering - Massachusetts Institute of Technology

E

Eugene Choi

Technical Advisor to the Defense Advanced Research Projects Agency - Strategic Analysis, Inc.

E

Eliana Clark

Vice President, Global Manufacturing Sciences - Biogen

M

Mel Koch

Principle Scientist, Center for Process Analysis and Control (CPAC) - University of Washington

M

Michael O’Brien

Senior Vice President, Global Science, Technology and Commercialization - Pfizer

Session III: Addressing barriers to the adoption of continuous manufacturing

P

Patricia Hurter

Senior Vice President, Global Pharmaceutical Development - Vertex

J

Johannes Khinast

Head of the Institute of Process and Particle Engineering, & Scientific Director, Research Center of Pharmaceutical Engineering (RCPE) - Graz University of Technology

R

Robin Robinson

Director, Biomedical Advanced Research and Development Authority, & Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health and Human Services

Session IV: Building stakeholder collaborations to facilitate the implementation of continuous manufacturing

C

Clive Badman

Head of Pre-Competitive Collaboration - GlaxoSmithKline

L

Liam Feely

Vice President, Manufacturing Science & Technology - AbbVie

G

Gintaras Reklaitis

Burton and Kathryn Gedge Distinguished Professor of Chemical Engineering - Purdue University

K

Keith Roper

Program Director, Engineering Research Centers - National Science Foundation

S

Seongkyu Yoon

Assistant Professor of Chemical Engineering - University of Massachusetts at Lowell

Closing remarks

More Information

Contact

To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.

More

Get a weekly events calendar from Brookings